In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. - Wikidata - wikimedia - TriplyDB

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

http://www.wikidata.org/entity/Q35001579

about

Novel immunotherapies in lymphoid malignancies Lymphoma Immunotherapy: Current Status CARs in chronic lymphocytic leukemia -- ready to drive Immune reconstitution in chronic lymphocytic leukemia Developing strategies in the immunotherapy of leukemias Evaluation of current cancer immunotherapy: hemato-oncology Adoptive T-cell therapy for Leukemia Strategies to genetically engineer T cells for cancer immunotherapy.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Antibody-based therapeutics for the treatment of human B cell malignancies "Model t" cells: a time-tested vehicle for gene therapy Chimeric antigen receptors (CARs) from bench-to-bedside.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?An in vivo mouse model of metastatic human thyroid cancer Antibody-modified T cells: CARs take the front seat for hematologic malignancies.New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future.Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.Adoptive immunotherapy for cancer.CAR T cells: driving the road from the laboratory to the clinic.Chimeric antigen receptor modified T cell therapy for B cell malignancies.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.CAR T-cell immunotherapy: The path from the by-road to the freeway?Engineered T cells: the promise and challenges of cancer immunotherapy.NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines.Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia.Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.Soluble CD23 measurement by CBA: a convenient and reliable quantification method in chronic lymphocytic leukemia.Low CD23 expression correlates with high CD38 expression and the presence of trisomy 12 in CLL.

P2860

Q26777394-8A3E3358-BD6C-4CDF-BB7E-D9E2147D3733 Q26782902-CD639348-9B70-47A3-8A4F-92FD2B169C45 Q26830526-75F18EDB-5716-4DCF-8939-A34039A164C6 Q26865561-5D34F848-B496-4F4B-A421-6BF44D5D7604 Q26996310-779E08B7-40E6-423D-8EAE-8501CA76B9CF Q27006179-E6C254E0-98C7-4B05-B17D-8DD4E1DD67C5 Q27006934-B5DF15FF-838F-43E3-A4F6-A0F105041C1F Q33655849-62385F61-4E96-46CE-823E-73ED8E70F0CC Q36366557-F8213E73-D3FE-4982-A833-1F9CBA3A95AE Q36386891-9D7592F7-85F1-4E69-9169-57171AFAEC21 Q36662079-0573A4BF-C6DD-4802-BA92-110D90E0CAA0 Q36907540-CD4178AC-A28D-49E8-B19E-AE24C499DCF0 Q37201423-436150C6-BA48-4538-AD86-6518A8818E93 Q37587780-59C246A9-704C-4C16-B40E-0AB614C7273D Q37587956-0734D781-7411-4E3E-A298-EA729725BA23 Q37712708-C7A8D6FA-A59A-47CD-8C34-1F3FC1CC83E4 Q37723469-A2354144-7778-4F90-9D22-A086E57D4547 Q37937083-64B8DFA2-ECE6-4F2B-A211-CEA91AA50181 Q37952805-5ED7865C-78D8-43F8-9E73-7416863C7726 Q38035043-B01FB00E-92A9-42D8-98FE-D8A23C572330 Q38049970-D139CF9B-9E4C-41F5-9F21-93EBD8A408DE Q38155343-91E8924D-A49F-4789-950A-0D2C13B7CA24 Q38170496-D5D03A48-3DE9-44ED-8E08-C75AEE0EE231 Q38170499-E5146F10-491C-423A-B469-149EC1B1E73E Q38171402-4D03EF00-810E-46B4-ACC4-41E3E64F22A0 Q38289029-BAFC6750-4993-4B40-B17E-663A990972BC Q38632105-3DE19DF7-F6D9-4F14-B896-9A2C3BD9DFDF Q38828829-43A5E3D9-C1A8-4633-AFEA-3E6B63173523 Q38892495-5A6EA184-45DA-457C-8CE8-B78C5ABCB05D Q40074476-0CF6623C-418A-495B-92F7-F4F2D0687222 Q42427577-EA705DA8-022D-41E8-B2D6-F229EB71E156 Q43599780-3E08EA8A-7842-416D-BA33-AD34898CBB9B Q53450213-4E2508DD-A0CD-40F1-AE33-2434CAE94370

P2860

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

http://www.wikidata.org/entity/Q35001579

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

In vitro and in vivo model of ...... D23 chimeric antigen receptor.

@ast

In vitro and in vivo model of ...... D23 chimeric antigen receptor.

@en

type

label

In vitro and in vivo model of ...... D23 chimeric antigen receptor.

@ast

In vitro and in vivo model of ...... D23 chimeric antigen receptor.

@en

prefLabel

In vitro and in vivo model of ...... D23 chimeric antigen receptor.

@ast

In vitro and in vivo model of ...... D23 chimeric antigen receptor.

@en

P1433

Q35001579-760BED45-10D8-4769-831D-94302EEE8B65

P1476

Q35001579-C506863F-1481-4BBD-91D9-9FB34AB6631A

P2093

Q35001579-03FDCB65-A52B-4997-BAB0-16F713BABEC4

Q35001579-1237F05A-7397-43B0-BDA1-BD8DC8BB05E7

Q35001579-3E2B7738-13EE-4A2D-8C50-250116F5AC04

Q35001579-8C3AE2B8-5BC3-4A48-853B-035040BEC02E

Q35001579-94C87323-89A3-4543-BA57-3574952D65D1

Q35001579-9DFDF5E6-9D84-460C-897C-39B1DAB53924

Q35001579-B2F61EB2-4FD7-4FFE-98C8-FAAEC96E3C3F

Q35001579-B8090643-5132-4C49-9C57-C0543036681C

Q35001579-C1A6DECE-46AB-45B4-8408-E20F25ACDA00

Q35001579-E0B040E7-C7CC-4089-8BE5-8F6973AA2EE3

P2860

Q35001579-0142F277-151A-4CB3-8135-67CDDCC3A386

Q35001579-07127896-889C-4B8B-9503-B742A06D9B71

Q35001579-081FC996-13AD-4042-87C6-F0B8310A9BF2

Q35001579-12991B1B-8B7A-4873-A14F-3F882EF0F9DC

Q35001579-16172831-3C67-4709-9847-C6D761E2C3D8

Q35001579-1B5DC1EE-BA39-48E8-8E3F-B9432D821D4C

Q35001579-1E0C7E4C-194F-428A-B486-C2FCC7598E07

Q35001579-35825DE1-C31B-4FAB-8874-183B246FFCFD

Q35001579-3D56D472-5B38-4BF2-8469-36FA294E3BDD

Q35001579-3F82AA36-9D97-413E-BD0F-46B6D671A174

P304

Q35001579-C517E922-A5C1-4F8A-9D89-F07A29B7EBEE

P31

Q35001579-052543E0-79F3-4773-BDE3-D31391FDE760

P356

Q35001579-D0FBB4EE-D7C5-499F-97DC-E6E576CD73FB

P407

Q35001579-37A5CA23-1B36-4294-83C0-F21B586F6333

P433

Q35001579-B6E907A3-CD7B-4CFC-BE22-8C7D2A6BEE00

P478

Q35001579-96C3F9DC-252B-46FE-AFC7-29A96799D307

P50

Q35001579-1D8BE7AB-1F94-4BF5-AF07-DEC01BCE33D9

Q35001579-64CDCE27-B69D-4D92-890D-49197DE980AE

Q35001579-8952958F-53AD-4787-830F-0962778B6D75

P577

Q35001579-C1EA7FBD-E41F-467D-B8C9-E468E7FC11B2

P5875

Q35001579-E2EB02FE-DE89-4F38-8DE3-C3A6A79F5695

P698

Q35001579-63EEDB5C-A73F-4C81-A2AA-28B8C267D552

P921

Q35001579-23BAE5C4-A2B1-4F51-B463-2E80F8839C39

Q35001579-72ADEF8D-AE61-4A48-89F3-711326673E8E

P932

Q35001579-50685997-4F53-4D9B-A373-59C8E33DC9F2

P356

BLOOD-2010-10-311845

P1433

P1476

In vitro and in vivo model of ...... D23 chimeric antigen receptor.

@en

P2093

Andrea Biondi

http://www.w3.org/2001/XMLSchema#string

Barbara Savoldo

http://www.w3.org/2001/XMLSchema#string

Ettore Biagi

http://www.w3.org/2001/XMLSchema#string

Gianpietro Dotti

http://www.w3.org/2001/XMLSchema#string

Greta Maria Paola Giordano Attianese

http://www.w3.org/2001/XMLSchema#string

Irene Pizzitola

http://www.w3.org/2001/XMLSchema#string

Maria T S Bertilaccio

http://www.w3.org/2001/XMLSchema#string

Matteo Parma

http://www.w3.org/2001/XMLSchema#string

Maurilio Ponzoni

http://www.w3.org/2001/XMLSchema#string

Valentina Hoyos

http://www.w3.org/2001/XMLSchema#string

P2860

Assembly PCR oligo maker: a tool for designing oligodeoxynucleotides for constructing long DNA molecules for RNA production.

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.

The promise and potential pitfalls of chimeric antigen receptors.

Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

P304

4736-4745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-10-311845

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Sarah Tettamanti

Valentina Agostoni

P577

2011-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50398764

http://www.w3.org/2001/XMLSchema#string

P698

21406718

http://www.w3.org/2001/XMLSchema#string

P921

P932

3100686

http://www.w3.org/2001/XMLSchema#string